HC Wainwright Cuts Earnings Estimates for Connect Biopharma

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of Connect Biopharma in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.27) for the quarter, down from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2025 earnings at ($0.29) EPS.

Connect Biopharma Price Performance

Shares of NASDAQ CNTB opened at $0.63 on Friday. Connect Biopharma has a 1 year low of $0.51 and a 1 year high of $2.29. The firm has a fifty day moving average price of $0.85 and a 200-day moving average price of $1.05.

Institutional Investors Weigh In On Connect Biopharma

A number of institutional investors have recently bought and sold shares of CNTB. Catalina Capital Group LLC purchased a new position in shares of Connect Biopharma in the fourth quarter valued at about $66,000. Callan Capital LLC grew its position in shares of Connect Biopharma by 91.3% during the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after purchasing an additional 38,177 shares in the last quarter. Finally, Choreo LLC bought a new stake in Connect Biopharma during the 4th quarter valued at approximately $204,000. Hedge funds and other institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.